IL2 and prostate carcinoma: Overall, these findings demonstrate that CTV-1 priming can enhance cytotoxic responses of patient NK cells toward a metastatic prostate cancer cell line, that is comparable to that of IL-2 stimulation, and that this enhancement appears to be irrespective of disease severity.